CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
CytomX Therapeutics (Nasdaq: CTMX), a leader in masked, conditionally activated biologic therapeutics, has announced it will report second quarter 2024 financial results on Thursday, August 8, 2024, after U.S. markets close. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT following the announcement. Investors can access the live webcast from CytomX's website and register for the conference call. Participants are advised to register at least 10 minutes before joining. An archived replay of the webcast will be available on the company's website for those unable to attend the live event.
CytomX Therapeutics (Nasdaq: CTMX), un leader nelle terapie biologiche mascherate e attivate condizionatamente, ha annunciato che riporter脿 i risultati finanziari del secondo trimestre 2024 gioved矛 8 agosto 2024, dopo la chiusura dei mercati statunitensi. L'azienda ospiter脿 una chiamata conferenza e una trasmissione webcast alle 17:00 ET / 14:00 PT subito dopo l'annuncio. Gli investitori possono accedere alla trasmissione in diretta dal sito web di CytomX e registrarsi per la chiamata conferenza. Si consiglia ai partecipanti di registrarsi almeno 10 minuti prima di unirsi. Una registrazione archiviata della trasmissione sar脿 disponibile sul sito dell'azienda per coloro che non possono partecipare all'evento dal vivo.
CytomX Therapeutics (Nasdaq: CTMX), un l铆der en terapias biol贸gicas enmascaradas y activadas condicionalmente, ha anunciado que reportar谩 los resultados financieros del segundo trimestre de 2024 el jueves 8 de agosto de 2024, despu茅s del cierre de los mercados en Estados Unidos. La compa帽铆a llevar谩 a cabo una videoconferencia y webcast a las 5:00 p.m. ET / 2:00 p.m. PT tras el anuncio. Los inversores pueden acceder a la transmisi贸n en vivo desde el sitio web de CytomX y registrarse para la conferencia. Se aconseja a los participantes registrarse al menos 10 minutos antes de unirse. Una reproducci贸n archivada del webcast estar谩 disponible en el sitio web de la empresa para aquellos que no puedan asistir al evento en vivo.
CytomX Therapeutics (Nasdaq: CTMX)電� 臁瓣贝鞝侅溂搿� 頇滌劚頇旊悳 毵堨姢韥� 靸濍頃� 旃橂鞝滌潣 靹犽憪欤检瀽搿滌劀 2024雲� 2攵勱赴 鞛 瓴瓣臣毳� 2024雲� 8鞗� 8鞚� 氇╈殧鞚�, 氙戈淡 鞁滌灔 膦呺 頉� 氚滍憸頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 氚滍憸 頉� 霃欕秬 響滌鞁� 鞓ろ泟 5鞁� / 韮滍弶鞏� 鞁滉皠 鞓ろ泟 2鞁�鞐� 鞝勴檾須岇潣 氚� 鞗轨簮鞀ろ姼毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛愲摛鞚� CytomX 鞗轨偓鞚错姼鞐愳劀 靸濎瓿勳棎 鞝戧芳頃� 靾� 鞛堨溂氅� 鞝勴檾須岇潣鞐� 霌彪頃� 靾� 鞛堨姷雼堧嫟. 彀戈皜鞛愲姅 斓滌唽 10攵� 鞝勳棎 霌彪頃� 瓴冹潉 甓岇灔頃╇媹雼�. 靸濎瓿勳棎 彀胳劃頃� 靾� 鞐嗠姅 攵勲摛鞚� 鞙勴暣 須岇偓 鞗轨偓鞚错姼鞐� 鞎勳勾鞚措笇霅� 鞛儩氤胳澊 鞝滉车霅� 鞓堨爼鞛呺媹雼�.
CytomX Therapeutics (Nasdaq: CTMX), un leader dans les th茅rapies biologiques masqu茅es et activ茅es de mani猫re conditionnelle, a annonc茅 qu'elle publiera les r茅sultats financiers du deuxi猫me trimestre 2024 le jeudi 8 ao没t 2024, apr猫s la fermeture des march茅s am茅ricains. La soci茅t茅 organisera une conf茅rence t茅l茅phonique et un webinaire 脿 17h00 ET / 14h00 PT suite 脿 l'annonce. Les investisseurs peuvent acc茅der au webinaire en direct depuis le site de CytomX et s'inscrire pour la conf茅rence t茅l茅phonique. Il est conseill茅 aux participants de s'inscrire au moins 10 minutes avant de rejoindre. Un enregistrement archiv茅 du webinaire sera disponible sur le site de la soci茅t茅 pour ceux qui ne peuvent pas assister 脿 l'茅v茅nement en direct.
CytomX Therapeutics (Nasdaq: CTMX), ein f眉hrendes Unternehmen im Bereich maskierter, bedingt aktivierter biologischer Therapeutika, hat bekannt gegeben, dass es am Donnerstag, den 8. August 2024, die finanziellen Ergebnisse f眉r das zweite Quartal 2024 nach dem Abschluss der US-M盲rkte bekannt geben wird. Das Unternehmen wird um 17:00 Uhr ET / 14:00 Uhr PT nach der Ank眉ndigung eine Telefonkonferenz und ein Webcast abhalten. Investoren k枚nnen den Live-Webcast 眉ber die Website von CytomX abrufen und sich f眉r die Telefonkonferenz registrieren. Den Teilnehmern wird geraten, sich mindestens 10 Minuten vor dem Eintritt zu registrieren. Eine archivierte Wiederholung des Webcasts wird f眉r diejenigen verf眉gbar sein, die nicht an der Live-Veranstaltung teilnehmen k枚nnen, auf der Unternehmenswebsite.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report second quarter financial results on Thursday, August 8, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at聽5:00 p.m. ET聽/聽2:00 p.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX鈥檚 website at聽. Participants may register for the conference call and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company鈥檚 website.
About聽CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY庐聽therapeutic platform, CytomX鈥檚 vision is to create safer, more effective therapies for the treatment of cancer. CytomX鈥檚 robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (鈥淎DCs鈥�), T-cell engagers, and immune modulators such as cytokines. CytomX鈥檚 clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule, EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CX-2051 was discovered in collaboration with Immunogen, now part of AbbVie. CX-801 is an interferon alpha-2b PROBODY庐聽cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas,聽Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit聽聽and follow us on聽听补苍诲听.
Company Contact:
Chris Ogden
Chief Financial Officer
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
Media Contact:
Redhouse Communications
Teri Dahlman
FAQ
When will CytomX Therapeutics (CTMX) report its Q2 2024 financial results?
What time is CytomX Therapeutics' (CTMX) Q2 2024 earnings call scheduled for?
How can investors access CytomX Therapeutics' (CTMX) Q2 2024 earnings webcast?
Will there be a replay available for CytomX Therapeutics' (CTMX) Q2 2024 earnings call?
